GPX3 and acute myeloid leukemia: The GPx-3-induced ROS decrease in leukemic cells, already reported in LICs [23], concomitantly associated with the antiproliferative effect of MSC contact, reinforces the therapeutic interest of targeting leukemic niche interactions to limit the niche-induced chemoresistance in AML.